ENDOU

Across TCGA pan-cancer cohorts, ENDOU Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ENDOU data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ENDOU Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENDOU expression acts as an unfavorable survival marker.

SCLC, LUAD, and SARC are the cancer types where ENDOU Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.164	0.625	.018	12	view →
LUAD	DFS	Median	All	0.098	0.768	<.001	12	view →
SARC	DFS	Median	All	0.109	0.591	.020	6	view →
HNSC	OS	Median	All	0.187	0.685	.042	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.125	0.654	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ENDOU–SCLC (DFS)

Open the SCLC breakdown →